BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 2479944)

  • 1. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
    Raju UB; Lee MW; Zarbo RJ; Crissman JD
    Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study.
    Gottlieb C; Raju U; Greenwald KA
    Mod Pathol; 1990 Mar; 3(2):135-40. PubMed ID: 1691493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of immunocytochemical markers in the differential diagnosis of proliferative and neoplastic lesions of the breast.
    Joshi MG; Lee AK; Pedersen CA; Schnitt S; Camus MG; Hughes KS
    Mod Pathol; 1996 Jan; 9(1):57-62. PubMed ID: 8821958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
    Moritani S; Kushima R; Sugihara H; Bamba M; Kobayashi TK; Hattori T
    Mod Pathol; 2002 Apr; 15(4):397-405. PubMed ID: 11950913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mammary lesions diagnosed as "papillary" by aspiration biopsy: 70 cases with follow-up.
    Simsir A; Waisman J; Thorner K; Cangiarella J
    Cancer; 2003 Jun; 99(3):156-65. PubMed ID: 12811856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
    Masood S; Loya A; Khalbuss W
    Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nipple aspirate fluid cytology in breast carcinoma.
    Krishnamurthy S; Sneige N; Thompson PA; Marcy SM; Singletary SE; Cristofanilli M; Hunt KK; Kuerer HM
    Cancer; 2003 Apr; 99(2):97-104. PubMed ID: 12704689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Moriya T
    J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
    J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary lesions of the breast: selected diagnostic and management issues.
    Collins LC; Schnitt SJ
    Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast.
    Gould VE; Koukoulis GK; Jansson DS; Nagle RB; Franke WW; Moll R
    Am J Pathol; 1990 Nov; 137(5):1143-55. PubMed ID: 1700618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
    Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
    Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad fibrovascular cores may not be an exclusively benign feature in papillary lesions of the breast: a cautionary note.
    Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Terasaki H; Nomura Y; Takenaka M; Naito Y; Akiba J; Yano H
    J Clin Pathol; 2014 Mar; 67(3):258-62. PubMed ID: 24062357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
    Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
    BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Needle core biopsy can reliably distinguish between benign and malignant papillary lesions of the breast.
    Carder PJ; Garvican J; Haigh I; Liston JC
    Histopathology; 2005 Mar; 46(3):320-7. PubMed ID: 15720418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
    de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
    Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ of the breast.
    Masood S; Sim SJ; Lu L
    Cancer Detect Prev; 1992; 16(4):225-35. PubMed ID: 1281040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions.
    Moriya T; Kanomata N; Kozuka Y; Fukumoto M; Iwachido N; Hata S; Takahashi Y; Miura H; Ishida K; Watanabe M
    Breast Cancer; 2009; 16(3):173-8. PubMed ID: 19475479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.